Case Studies In Benign Prostatic Hyperplasia

Each of the 41 case studies presented puts the patient and his symptoms into context, describing the urological history and results of physical examinations, presenting the patient's voiding diary, and depicting the results of a variety of different urodynamic examinations with the use of traces and photographs.

Twenty-three case studies that provide a concise and focused overview of the management of prostatic disorders, closely reflecting the day-to-day clinical problems faced by experienced and trainee urologists. Covers benign prostatic hyperplasia, prostate cancer, and prostatitis.

This report presents one example of the advocacy of evidence-based medicine in the hospital setting, namely the Laser Treatment of Benign Prostatic Hyperplasia (BPH) Technology Assessment (TA) project at the greater Victoria Hospital Society (GVHS). The report begins with a definition of health technology assessment (HTA), then describes the Technology Assessment Committee (TAC) at GVHS, and provides background material on surgical treatment of BPH in general, and laser treatment in particular. The report describes how the TAC brought together, into one venue, representatives from four disparate groups. Although the TAC brought the groups together, it did not bring about consensus, as each group entered into, and largely maintained, a different conceptual framework, value system, and practical agenda, with: the laser industry arguing "the needs for progress"; the GVHS urologists and administrators arguing "the need to compete with other hospitals"; BCOHTA arguing "the need for research and evaluation". The report then focusses on debates about efficacy and effectiveness evidence. The report concludes that integrating an appraisal of the efficacy and effectiveness evidence into the TA process, while helping to clarify the state of knowledge for laser treatment of BPH, does not solve the problem of deciding which technology to purchase for treatment of BPH. Rather, adding a critical appraisal of the effectiveness claims to systematic review and debate.

Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: From Research to Bedside offers full acknowledgment of the basic research of lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH), also connecting the clinical and practice management of the disease. It provides a full comprehension of LUTS and BPH from several aspects, allowing for a schematic interpretation of the disease and subsequent medical management. Going beyond the guidelines in the field, this title enhances the knowledge of BPH onset, allowing for the advancement of research, beneficial clinical implication and treatment. Perfect for researchers, urologists, pathologists and endocrinologists, this must-have reference provides what is needed to understand LUTS and BPH in one easy to reference place. Provides a clear understanding of the pathological mechanisms that are present in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) Incorporates research with the clinical aspects of LUTS and BPH, including surgical techniques Presents an overview of LUTS and BPH in one easy to reference place

Blandy's Urology, 3rd edition is set to become a classic in its field, the latest edition of one of the most well-loved general urology textbooks for urologists and surgeons alike, successfully combining both general urology and urologic surgery. Its key strength is the unique ‘Blandy way’ of describing urological diseases and their management, consisting of: clear, straightforward, uncomplicated descriptions of disease/conditions, including hundreds of clinical photos an abundance of outstanding drawn surgical diagrams to illustrate best technique in the operating theatre a focus on the most commonly seen problems in the clinic organization of each topic under anatomical headings Especially loved by urology and surgery trainees for its straightforward approach to the speciality and as a preparation for speciality urology exams, consultants and specialists also value it as a handy refresher tool.

Benign prostatic hyperplasia (BPH) is an age-related, nonmalignant condition that may lead to bothersome lower urinary tract symptoms. The standard treatment of BPH has been ordinary loop transurethral prostatectomy, but new therapies have been developed as a combined result of research, technological advances, and the cumulative experience of urological surgeons. Among the most promising therapeutic alternatives to ordinary loop resection are those that deliver topical or interstitial heat to prostatic tissue. Transurethral microwave thermotherapy, visual laser ablation with the Nd:YAG laser, high-intensity focused ultrasound, and transurethral electrovaporization are some of the techniques described in this book. These innovative procedures, employed by skilled urologists using state-of-the-art instruments, hold forth the promise of improved quality of life for BPH patients and represent significant advances in the field of urology.

Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5α-reductase inhibitors, DFMO and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.